Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

ABSTRACT:

SUBMITTER: Kutsch N 

PROVIDER: S-EPMC9208895 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature